These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37506145)

  • 1. Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.
    Onodera M; Uchiyama T; Ariga T; Yamada M; Miyamura T; Arizono H; Morio T
    Immun Inflamm Dis; 2023 Jul; 11(7):e917. PubMed ID: 37506145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
    Dorsey MJ; Rubinstein A; Lehman H; Fausnight T; Wiley JM; Haddad E
    J Clin Immunol; 2023 Jul; 43(5):951-964. PubMed ID: 36840835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
    Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
    J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Immune Reconstitution in ADA-Deficient Patients Treated With Elapegademase: A Real-World Experience.
    Murguia-Favela L; Suresh S; Wright NAM; Alvi S; Tehseen S; Hernandez-Trujillo V; Seroogy CM; Haddad E; Nieves D; Hershfield MS; Walter JE; Pettiford L; Kamani NR; Keller MD; Pham-Huy A; Grunebaum E
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1725-1733. PubMed ID: 36736953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of elapegademase and pegademase in ADA-deficient patients and mice.
    Murguia-Favela L; Min W; Loves R; Leon-Ponte M; Grunebaum E
    Clin Exp Immunol; 2020 May; 200(2):176-184. PubMed ID: 31989577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.
    Moretti FA; Giardino G; Attenborough TCH; Gkazi AS; Margetts BK; la Marca G; Fairbanks L; Crompton T; Gaspar HB
    Sci Rep; 2021 Dec; 11(1):23221. PubMed ID: 34853379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
    Tartibi HM; Hershfield MS; Bahna SL
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
    Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
    J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy.
    Grunebaum E; Reid B; Naqvi A; Hershfield MS; Kim VH; Muller MP; Hicks LK; Lee E; Betschel S; Roifman CM
    Clin Immunol; 2020 Feb; 211():108321. PubMed ID: 31812707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase.
    Bax BE; Bain MD; Fairbanks LD; Webster AD; Chalmers RA
    Br J Haematol; 2000 Jun; 109(3):549-54. PubMed ID: 10886203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency.
    la Marca G; Canessa C; Giocaliere E; Romano F; Duse M; Malvagia S; Lippi F; Funghini S; Bianchi L; Della Bona ML; Valleriani C; Ombrone D; Moriondo M; Villanelli F; Speckmann C; Adams S; Gaspar BH; Hershfield M; Santisteban I; Fairbanks L; Ragusa G; Resti M; de Martino M; Guerrini R; Azzari C
    J Allergy Clin Immunol; 2013 Jun; 131(6):1604-10. PubMed ID: 23280131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
    Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
    Front Immunol; 2018; 9():113. PubMed ID: 29456531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
    Chaffee S; Mary A; Stiehm ER; Girault D; Fischer A; Hershfield MS
    J Clin Invest; 1992 May; 89(5):1643-51. PubMed ID: 1569204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
    Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
    Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.